AT-13387
CAS: 912999-49-6
Ref. 3D-FA145338
5mg | 172,00 € | ||
10mg | 248,00 € | ||
25mg | 436,00 € | ||
50mg | 582,00 € | ||
100mg | 863,00 € |
Produktinformation
- Onalespib
- (2,4-Dihydroxy-5-isopropylphenyl)[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone
- (2,4-Dihydroxy-5-propan-2-ylphenyl)-[5-[(4-methylpiperazin-1-yl)methyl]-1,3-dihydroisoindol-2-yl]methanone
- 1H-Isoindole, 2-[2,4-dihydroxy-5-(1-methylethyl)benzoyl]-2,3-dihydro-5-[(4-methyl-1-piperazinyl)methyl]-
- At 13387X
- At-13387
- Ati 3387
- Methanone, [1,3-dihydro-5-[(4-methyl-1-piperazinyl)methyl]-2H-isoindol-2-yl][2,4-dihydroxy-5-(1-methylethyl)phenyl]-
- [1,3-Dihydro-5-[(4-methyl-1-piperazinyl)methyl]-2H-isoindol-2-yl][2,4-dihydroxy-5-(1-methylethyl)phenyl]methanone
AT-13387 is a potent and selective HSP90 inhibitor that binds to the ATP binding site of HSP90 with high affinity. It has been shown to inhibit the proliferation of HL-60 cells in vitro. AT-13387 induces apoptosis in cancer cells by inhibiting the signaling pathways involved in regulating cell growth, including the activation of toll-like receptor 4 (TLR4). The efficacy of AT-13387 was evaluated in vivo using an animal model with bowel disease, which showed significant inhibition of tumor growth. AT-13387 also inhibits TLR4 signaling, suggesting that it may be useful for treating bowel disease. AT-13387 is being developed as a potential therapy for cancer and other diseases associated with TLR4 activation.
Chemische Eigenschaften
Technische Anfrage zu: 3D-FA145338 AT-13387
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.